All Categories

Industry News

Home > News > Industry News

EU assesses the safety of Amaferm® as a feed additive for dairy cattle

View: 46 Author: Site Editor Publish Time: 2022-02-17 Origin: site

On February 7, 2022, according to the European Food Safety Authority (EFSA), at the request of the European Commission, the European Union Animal Feed Additives and Products (FEEDAP) research group issued a scientific opinion on the safety of Amaferm® as a dairy cattle feed additive.

It is understood that Amaferm® is the fermentation product of Aspergillus oryzae strain NRRL 458, which contains alpha-amylase and cellulase activities. Some of the original reports are as follows:

Amaferm® is a fermentation product produced by Aspergillus oryzae NRRL 458, containing alpha-amylase and cellulase enzyme activities, authorised for use as a feed additive for dairy cows. In 2016, the applicant requested for the renewal of the authorisation and the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) issued an opinion at that regard in 2020. In that opinion, the Panel could not confirm the previously drawn conclusions (EFSA, 2006) regarding the safety of the production strain, and consequently could not confirm the safety of the additive for the target species and consumers. In the current submission, the applicant provided supplementary information that allowed the Panel to conclude on the identity of the production strain, redefine the specifications of the additive, and finally to conclude on its safety. Therefore, the new data provided permit to conclude that Amaferm® complies with the conditions of the authorisation. However, the Panel noted that there is the need to change the specification and description of the cellulase and amylase units in the authorisation act. The data provided in the previous (EFSA FEEDAP Panel, 2020) and the current assessments support that Amaferm® remains safe under the approved conditions for target species, consumers and the environment. The additive is non-irritant to skin and eyes, or a dermal sensitiser but should be considered a potential respiratory sensitiser.